BioMarin Pharmaceutical Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BMRN Nasdaq 2830 www.biomarin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioMarin Pharmaceutical Inc.

Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Jun 8th, 2026 4:47 am
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Jun 5th, 2026 12:08 am
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Jun 3rd, 2026 9:30 am
Centene, Deckers and 14 Other ‘Dividend Hopefuls’ - Jun 1st, 2026 11:30 pm
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year - May 30th, 2026 11:56 am
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - May 30th, 2026 10:43 am
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - May 28th, 2026 2:27 pm
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - May 22nd, 2026 11:00 pm
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky - May 22nd, 2026 12:44 pm
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint - May 21st, 2026 7:29 am
BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency - May 20th, 2026 5:12 pm
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia - May 20th, 2026 2:20 pm
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study - May 19th, 2026 10:56 am
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls - May 19th, 2026 7:34 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More - May 19th, 2026 6:04 am
BioMarin drug acquired in buyout misses goal in rare disease study - May 19th, 2026 5:58 am
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency - May 18th, 2026 7:05 am
2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down - May 17th, 2026 11:32 pm
A Look At BioMarin Pharmaceutical (BMRN) Valuation As Guidance Rises And New VOXZOGO Data Emerges - May 14th, 2026 5:16 am
BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions - May 13th, 2026 5:24 pm